Detalhe da pesquisa
1.
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Lancet Oncol;
25(2): 175-183, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38218192
2.
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging;
49(10): 3581-3592, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35384462
3.
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Eur J Nucl Med Mol Imaging;
46(1): 129-138, 2019 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30232539
4.
Correction to: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Eur J Nucl Med Mol Imaging;
46(10): 1988, 2019 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31240331
5.
Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617.
Eur J Nucl Med Mol Imaging;
46(8): 1756-1757, 2019 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31115638
6.
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging;
44(6): 1099-1100, 2017 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28255795
7.
mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
J Nucl Med;
63(10): 1496-1502, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35177427
8.
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy.
J Nucl Med;
61(1): 62-69, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31101746